會議主題： 腸胃道癌症免疫治療新紀元：從基礎研究到臨床實務
會議時間： 2026 年 7 月 11 日（星期六）14：00 – 17：00
共同贊助：臺灣百濟神州有限公司(瑞士商 BeOne Medicines)、台灣小野藥品工業股份有限公司、台灣必治妥施貴寶股份有限公司
會議平台： Google Meet
學分：藥師、護理師、專科護理師繼續教育積分申請中~
線上學員如有積分需求，需完成線上簽到退-（合計2次-簽到、簽退）及課後需完成「滿意度問卷」方能給予積分，請學員週知。

因目前報名人數已達會場容納上限，為維持研討會整體的學術交流與互動品質，本會已提前關閉報名表單，截止報名。對於未能成功報名的夥伴，我們深表遺憾與歉意。 為了讓更多醫事同仁共襄盛舉，本次研討會之課程內容，後續將於整理後上傳至學習平台。

 

New Educational Reinforcement Additions to this Series! Series Includes Free Immunizations CE   In this 1.5-hour online activity, experts shed light on the latest updates in pneumococcal disease and vaccinations, including updated guideline recommendations, how to apply them to different patient populations, and innovations to increase pharmacist administration of vaccines and associated patient education.  We invite you to share this free educational activity with your colleagues.   PharmD, Activity Chair    Clinical Pharmacy Specialist– Infectious Diseases
Beth Israel Deaconess Medical Center
Boston, Massachusetts PharmD, BCPPS, FPPA   Clinical Pharmacy Specialist; Pediatric Infectious Diseases Antimicrobial Stewardship Co-Lead
Children's Hospital of the
King's Daughters
Norfolk, Virginia This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, ambulatory clinics, and community settings who manage patients at risk for pneumococcal disease in children and adults. Welcome and Introductions
  Epidemiology, Burden, Invasive vs. Noninvasive Disease, and Pediatric Risk Factors  Sarah Parsons
  Adult Risk Factors
Vaccine Composition Studies and Serotypes   Monica Mahoney
  Pediatric Vaccination Schedules  Sarah Parsons
  Adult Vaccine Schedules
Incorporating Vaccination and Education into Workflow Monica Mahoney   Faculty Discussion, Questions and Answers All Faculty   ACPE #: 0204-0000-25-418-H06-P CE Credit: 1.5 contact hours (0.15 CEUs) Activity Type: Application-based Activity Fee: No charge Available: February 19, 2026 - February 19, 2027
To receive CE credit, complete the steps below within 60 days of completing the activity. After the 60-day deadline, ASHP will no longer be able to report credit(s).

Upcoming ASHP On-Demand Activities FEATURED ON-DEMAND RESOURCES View all recorded webinars →   This educational activity will include evidence-based care and best practices for identifying and addressing barriers and social determinants of health that impact CKM syndrome. The latest evidence focused on the use of SGLT2 inhibitors on cardiovascular and kidney outcomes will be discussed and applied to individualized patient cases.    New Release! CE Webinar   This educational activity discusses the pathophysiology of Chronic Inflammatory Demyelinating Polyneuropathy as well as the incidence, prevalence, clinical course, and burden of disease. A review of the current guideline-recommended therapies will be discussed, including any treatment limitations.    New Release! CE Webinar   This educational activity will present the cardiovascular risks of CKD and discuss approaches to identify and screen patients at risk for CKD. Real-world examples of best practices in multidisciplinary care and patient education will be shared to equip and inspire pharmacists to bridge gaps across the cardiovascular-kidney-metabolic spectrum.    New Release! CE Webinar   This educational program reviews root causes and economic factors that contribute to sterile injectable supply disruptions and drug shortages and provides collaborative solutions for supply availability and ensuring long-term sustainability.    New Release!

Just Released!
Free On-Demand Patient Safety CE on Parenteral Nutrition Parenteral nutrition (PN) is a life-sustaining intervention for patients unable to receive oral or enteral nutrition. Compounding of PN involves many steps that can be labor intensive to ensure that PN is accurately and aseptically produced. An approach to improving standardization to reducing errors and patient harm is through greater use of multi-chamber bag parenteral nutrition (MCB-PN). MCB-PN requires less preparation time and labor, leads to a reduction in errors, may reduce the risk of infectious complications leading to a reduction in the length of hospitalization, and is associated with a significant cost benefit compared with compounded PN. MCB-PN reduces the compounding required by pharmacists but still allows for the addition of additives prior to administration.   This educational activity will discuss appropriate patient selection for multi-chamber bag parenteral nutrition (MCB-PN) and how to safely prepare and dispense MCB-PN. This activity will also use a case-based approach to illustrate strategies to reduce the risk of errors and improve patient care in various practice settings. The activity will highlight the important role of the pharmacist in parenteral nutrition, including in healthcare settings without formal nutrition support teams.   We invite you to share this free educational activity with your colleagues.    PharmD, BCNSP, FMSHP, FASHP, FASPEN  Activity Chair   Clinical Manager Mississippi Baptist Medical Center Clinical Associate Professor University of Mississippi School of Pharmacy Jackson, Mississippi PharmD, BCCCP, BCNSP, BCPS, FASHP, FASPEN, FCCM, FCCP      Chair and Clinical Professor Philadelphia College of Pharmacy Saint Joseph's University Philadelphia, Pennsylvania This activity was planned to meet the educational needs of pharmacists in leadership positions including pharmacy executives, managers and supervisors, front-line clinical pharmacists and those in product procurement roles who can identify specific opportunities for multi-chamber bag parenteral nutrition (MCB-PN).                        Welcome and Introductions
Phil Ayers 
  Parenteral Nutrition and the Important Role of Multi-Chamber Bag Parenteral Nutrition (MCB-PN)                                                         Phil Ayers and Angela Bingham      
Interactive Case Presentations and Discussion: Safety First! Effectively Using MCB-PN   All Faculty
  Pharmacist Involvement in Nutrition in a Practice Setting Without a Nutrition Support Service  All Faculty
  Faculty Discussion, Questions and Answers All Faculty   ACPE #: 0204-0000-25-413-H05-P CE Credit: 1.5 contact hours (0.15 CEUs) Activity Type: Application-based Activity Fee: No charge  Available: February 26, 2026 - February 26, 2027   To receive CE credit, complete the steps below within 60 days of completing the activity. After the 60-day deadline, ASHP will no longer be able to report credit(s).  To view all of the live activities offered in person and online, click here.

Newly Released Free, On-Demand CE! Pharmacists can bridge the gap in ASCVD care with lipid screening, optimization of LDL-C lowering medication therapy, and improving medication adherence. In this program, experts will review updated guideline recommendations for ASCVD risk assessment and treatment; explore statin and nonstatin medications including current and emerging PCSK9 inhibitors; describe strategies for overcoming barriers to achieving LDL-C thresholds; and expand on strategies for increased patient engagement and shared decision-making to optimize outcomes. We invite you to share this free educational activity with your colleagues. PharmD, FASHP, MNLA, BCPS, BCACP, Activity Chair    Associate Dean for Clinical Affairs, Professor, Department of Clinical Pharmacy; Professor, Department of Family Medicine 
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus 
Aurora, Colorado PharmD, BCPS, CLS, FNLA, FASPC   Clinical Pharmacist, General Cardiology 
Knight Cardiovascular Institute, Oregon Health & Science University
Portland, Oregon This activity was planned to meet the educational needs of pharmacists who practice in hospitals, health systems, specialty pharmacies, ambulatory clinics, and community settings who manage patients at high risk for ASCVD or who have clinical ASCVD.  Analyze the role of LDL-C in ASCVD and the importance of achieving LDL-C thresholds to reduce the risk of ASCVD events. Prioritize lipid screening and risk stratification for patients at high risk for ASCVD and with clinical ASCVD, including patients with heterozygous familial hypercholesterolemia, at-risk populations, and patients with high unmet needs.  Examine benefits and risks of current and emerging LDL-C lowering pharmacotherapies.  Apply current guideline-based recommendations to the treatment of patients at high risk for ASCVD and with clinical ASCVD who are eligible for nonstatin therapies including PCSK9 inhibitors.   Welcome and Introductions
Joseph Saseen
  Overview of Atherosclerosis Bruce A. Warden
  Evidence-based Management of Hypercholesterolemia   Joseph Saseen
  Statin and Nonstatin Medications Joseph Saseen
  Achieving Recommended LDL-C Thresholds to Reduce ASCVD Event Risk Bruce A. Warden
  Faculty Discussion, Questions and Answers All Faculty ACPE #: 0204-0000-25-417-H01-P CE Credit: 1.5 contact hours (0.15 CEUs) Activity Type: Application-based Activity Fee: No charge  Available: February 19, 2026 - February 19, 2027
To receive CE credit, complete the steps below within 60 days of completing the activity. After the 60-day deadline, ASHP will no longer be able to report credit(s).